AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) has received acceptance from the NYSE American for its compliance plan to meet minimum stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. The company has been granted until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards. CEO Thomas K. Equels expressed satisfaction with the approval and mentioned ongoing developments in the company's oncology and antiviral pipelines.

Positive

• NYSE American accepted compliance plan
• Extended deadline until June 2026 to meet requirements
• Ongoing development in oncology and antiviral pipelines

Negative

• Company currently non-compliant with NYSE American equity requirements
• Risk of potential delisting if compliance not achieved by June 2026

Insights

Financial Analyst

AIM ImmunoTech's successful negotiation with NYSE American provides critical breathing room for this struggling micro-cap biotech. The exchange's acceptance of AIM's compliance plan grants the company until June 2026 to meet minimum stockholders' equity requirements - likely in the $4-6 million range based on the cited sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.

This extended timeline is particularly significant for AIM given its precarious financial position with a market cap of just $9.2 million. The company now has approximately 16 months to execute its strategy, which will almost certainly require substantial capital raising activities through either equity offerings, partnerships, or asset monetization.

For investors, this development prevents an immediate forced selling scenario that would typically accompany delisting, but introduces several key considerations:

• AIM must demonstrate meaningful progress in its oncology and antiviral pipelines to attract the capital needed to meet equity requirements
• Any equity raises will likely come at dilutive terms given the penny stock status ($0.1239 per share)
• Maintaining NYSE American listing is important for institutional investment access and future financing options

While this announcement temporarily removes an existential threat, investors should closely monitor upcoming quarterly reports for cash burn rate, pipeline milestone achievements, and any strategic transactions that could improve AIM's equity position. The company's ability to advance its clinical programs while simultaneously addressing these compliance issues will determine whether this reprieve becomes a turning point or merely delays an inevitable delisting.

OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s Plan to regain compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. AIM has until June 11, 2026 to regain compliance with the NYSE’s Continued Listings Standards.

AIM CEO Thomas K. Equels stated: “We are pleased that the NYSE American has approved our plan and look forward to executing the strategy over the coming months as we also continue to make advancements in our oncology and antiviral pipelines.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This current report, including exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. There can be no assurance that the Company will be able to achieve compliance with the American’s continued listing standards within the required timeframe. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this current report. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

FAQ

What is the deadline for AIM ImmunoTech to regain NYSE American listing compliance?

AIM ImmunoTech has until June 11, 2026 to regain compliance with NYSE American's minimum stockholders' equity requirements.

Which NYSE American listing requirements does AIM need to comply with?

AIM needs to comply with Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide regarding minimum stockholders' equity requirements.

What happens if AIM fails to meet NYSE American compliance by June 2026?

If AIM fails to meet compliance by June 11, 2026, the company could face delisting from the NYSE American exchange.

What areas of development is AIM ImmunoTech currently focusing on?

AIM ImmunoTech is focusing on developments in their oncology and antiviral pipelines.